Clinical trials
Cardiomyopathies clinical trials
Below are recruiting cardiomyopathies clinical trials, each written for real people, not researchers. We’re tracking 322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07595354Recruiting
Safe Exercise Plan for Young People at Risk of Heart Disease
This study helps children and teens who may be at risk for a heart condition called HCM learn safe ways to exercise. Researchers will create a personalized exercise plan and check in regularly to see how it goes.
LiverpoolAges 10–18 - NCT07600177RecruitingPhase 4
Switching Heart Medicines: Mavacamten to Aficamten
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
Kansas City, MissouriAges 18–90 - NCT07563660Recruiting
Heart imaging study for arrhythmogenic right ventricular cardiomyopathy
This study uses a special type of heart scan (FAPI PET/CT) to better visualize and understand arrhythmogenic right ventricular cardiomyopathy (ARVC), a condition where the heart muscle weakens and causes irregular heartbeats. The scan may help doctors understand the disease better and improve patient care.
Istanbul, FatihAges 18 years+ - NCT07557498Recruiting
Mavacamten Outcomes and Experiences in Heart Muscle Disease
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Bollington, MacclesfieldAges 18 years+ - NCT07541833Recruiting
Mavacamten Treatment Patterns in Obstructive Heart Thickening
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Minato-ku, TokyoAges 18 years+ - NCT07527715Recruiting
Heart MRI Study for Dilated Heart Muscle Disease
This research uses cardiac MRI scans and patient data to better predict outcomes in people with dilated cardiomyopathy—a condition where the heart's main pumping chamber becomes enlarged and weakened. Participating could help doctors improve how they care for similar patients in the future.
Jinan, ShandongAges 18 years+ - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07505199RecruitingPhase 1
Immune cell therapy for advanced heart failure from blocked arteries
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07491718Recruiting
MRI with manganese for takotsubo cardiomyopathy
This study uses a special MRI with a contrast agent called manganese to look at how the heart works in people with takotsubo cardiomyopathy (broken heart syndrome). It may help doctors understand why this condition happens and how to treat it better.
EdinburghAges 18 years+ - NCT07491237Recruiting
Heart rhythm and function study
This study looks at how heart rhythm problems affect heart function. It may help doctors better understand and treat these conditions.
RomaAges 18 years+ - NCT06793020Recruiting
Study of sepsis-related heart damage using a math model
This trial tests a new mathematical model to better diagnose and treat heart problems caused by sepsis. It includes adults with sepsis or septic shock who need strong blood pressure support.
VilniusAges 18 years+ - NCT06688396Recruiting
Finding early signs of dilated cardiomyopathy with AI and mobile screening
This trial uses a smartphone app to screen first-degree relatives of people with dilated cardiomyopathy (DCM) for early signs of the condition. It aims to detect heart muscle weakness before symptoms start, so that treatment can begin sooner.
Lancaster, PennsylvaniaAges 18 years+ - NCT07443696RecruitingPhase 2
Heart imaging test to see if bypass surgery could help
This study uses two imaging scans to see if parts of your heart muscle are still alive but not working well. This could help doctors decide if you might benefit from heart bypass surgery.
Beijing, Beijing MunicipalityAges 18–85 - NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80 - NCT07398950Enrolling by invitation
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT07383025Recruiting
Mavacamten safety study for heart muscle disease in Japan
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
TokyoAges 18 years+ - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT07381894Recruiting
Hypertrophic cardiomyopathy patient registry
This registry collects information about people with hypertrophic cardiomyopathy (HCM) to better understand the condition and improve care. It is for patients who have a confirmed HCM diagnosis not caused by other issues.
ManchesterAges 18–99 - NCT07372196Recruiting
Left bundle branch pacing after myectomy for hypertrophic cardiomyopathy
This trial is testing a new way to pace the heart (left bundle branch pacing) for people with hypertrophic cardiomyopathy who still have a dangerous heart rhythm problem after myectomy surgery. It aims to see if this pacing can reduce the risk of sudden cardiac death.
Novosibirsk, Novosibirsk OblastAges 18–75 - NCT07367724RecruitingPhase 2
Ademetionine for obstructive hypertrophic cardiomyopathy
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
BeijingAges 18 years+ - NCT06224660RecruitingPhase 1
Gene therapy for heart problems in Duchenne muscular dystrophy
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
Kansas City, KansasAges 18 years+ - NCT07361289Recruiting
Mavacamten for obstructive hypertrophic cardiomyopathy in China
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07344480Recruiting
Study on heart disease in children with RASopathy
This study looks at medical records of children with a genetic condition called RASopathy who developed thickened heart muscle and needed hospital care for heart failure in their first six months of life. The goal is to understand how the heart condition progresses over time.
MünchenAges Any age - NCT07351838Recruiting
Heart MRI for risk screening in early cardiomyopathy
This study uses heart MRI to find people with early signs of heart muscle disease who still have normal-sized heart chambers. It aims to better predict who is at risk so they can get earlier care.
BeijingAges 16 years+
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiomyopathies?
- Yes. Clin2 currently lists 322 recruiting cardiomyopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiomyopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.